| 04.12.18 | GSK hands off rare disease unit; Another day, another 'vant'—this one's for RNA

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

6 jahre vor

Html
Text

To view this email as a web page, click here

Today's Rundown

GlaxoSmithKline offloads rare disease gene therapies to Orchard Therapeutics Roivant, Arbutus set up RNA JV, put ex-Ariad, Roche executives in leadership posts Abpro files $69M IPO to take bispecific antibodies into the clinic Bellicum shares jump as FDA lifts clinical hold Versant, Novartis power cystic fibrosis startup Enterprise Therapeutics to series B round FDA relaxes clinical hold on Translate Bio’s cystic fibrosis drug Gene-targeted animal model CRO Biocytogen nets $65M series C, eyes global expansion

This week's sponsor is TD2.
	6 Signs You Need a New CRO for Your Preclinical Research Are your preclinical studies where they deserve to be? If progress has stalled, maybe it's your CRO that's the problem...not you. Learn these six telltale signs it's time to switch. Fast-Track Your Research with TD2.

Featured Story

GlaxoSmithKline offloads rare disease gene therapies to Orchard Therapeutics

Thursday, April 12, 2018

Orchard is picking up a pair of late-phase candidates, as well as the EMA-approved "bubble-boy" med Strimvelis. The move comes nine months after GlaxoSmithKline announced it was considering selling off its rare disease portfolio.

This week's sponsor is Deloitte.

Roivant, Arbutus set up RNA JV, put ex-Ariad, Roche executives in leadership posts

Thursday, April 12, 2018

Roivant and Arbutus have pooled their resources to create an RNA-focused biotech, Genevant. The startup begins life with RNA delivery technology from Arbutus, $37.5 million in seed funding from Roivant and plans to take 5 to 10 programs into the clinic by 2020.

Abpro files $69M IPO to take bispecific antibodies into the clinic

Thursday, April 12, 2018

Preclinical-stage biotech Abpro Therapeutics has filed a $69 million IPO that it hopes will fund clinical trials of its lead antibody drugs for cancer and vascular eye disease due to start next year.

Bellicum shares jump as FDA lifts clinical hold

Wednesday, April 11, 2018

The FDA lifted a clinical hold it placed on Bellicum's lead cell therapy, BPX-501, in January, after learning of three cases of brain damage.

Versant, Novartis power cystic fibrosis startup Enterprise Therapeutics to series B round

Thursday, April 12, 2018

Versant Ventures and Novartis Venture Fund have co-led a £29 million ($41 million) series B round in cystic fibrosis disease startup Enterprise Therapeutics. The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.

FDA relaxes clinical hold on Translate Bio’s cystic fibrosis drug

Thursday, April 12, 2018

The first trial of Translate Bio's nebulized messenger RNA therapy is now due to start in mid-2018, with results due a year later.

Gene-targeted animal model CRO Biocytogen nets $65M series C, eyes global expansion

Thursday, April 12, 2018

Biocytogen, a Chinese CRO specialized in gene-targeted animal models and related services, has just closed a $65 million series C round. It plans to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

This week's sponsor is Sensors Expo.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Resources

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

[Whitepaper] The Future of Life Sciences Events Management

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

[Whitepaper] 2018 Life Sciences Trends

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Presented by: Patheon, part of Thermo Fisher Scientific

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

Presented by: Charles River

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Presented by: Covance

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.